Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study

Introduction To date the early strut coverage with the second-generation durable-polymer ONYX zotarolimus-eluting stent (O-ZES) is unknown. Aim Optical coherence tomography (OCT) assessed the strut coverage of O-ZES at thirty-day follow-up. Material and methods OCT was performed after implantation and at 1-month follow-up in 15 patients treated with O-ZES. Results Mean patient age was 67 ±7 years (73% males). The clinical presentation consisted of acute coronary syndromes (n = 13) and stable coronary disease (n = 2). Four (26%) patients had diabetes. OCT analysis was performed at baseline and 1-month follow-up in all stents. 378 cross-sections with 3582 struts were assessed at baseline and 3661 at follow-up. At follow-up, 88% struts were covered by tissue with a median thickness 37.91 μm (IQR: 22.32–64.15). Median in-stent area obstruction by neointima was 2.64% (IQR: 1.70–4.84). From the total stent covered area, 92.3% showed complete strut coverage. Homogeneous tissue was observed in 74% of cases. There were no differences in minimal lumen area (5.07 ±1.08 mm2 vs. 4.81 ±0.94 mm2, p = 0.125) or minimal stent area (4.95 ±1.22 mm2 vs. 4.92 ±0.99 mm2) at baseline and at follow-up. There were no differences in the rate of strut malapposition (4.3% vs. 5.7%, p = 0.417). For all stents, malapposition volume was 47.9 mm3 at baseline and 51.7 mm3 at follow-up, giving the late acquired stent malapposition volume of 3.8 mm3. Conclusions The second-generation durable polymer O-ZES showed favorable vessel healing at 30-day OCT follow-up.

[1]  D. Dudek,et al.  An optical coherence tomography study of neointimal morphology and strut coverage at different time intervals from implantation of biodegradable polymer‐coated sirolimus‐eluting stents , 2018, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[2]  T. Sawada,et al.  Comparison of the 9-month intra-stent conditions and 2-year clinical outcomes after Resolute zotarolimus-eluting stent implantation between 3-month and standard dual antiplatelet therapy. , 2018, Journal of cardiology.

[3]  M. Sabaté,et al.  Three‐ and 6‐month optical coherence tomographic surveillance following percutaneous coronary intervention with the Angiolite® drug‐eluting stent: The ANCHOR study , 2018, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[4]  Shigeru Saito,et al.  First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter. , 2017, JACC. Cardiovascular interventions.

[5]  R. D. de Winter,et al.  The REMEDEE-OCT Study: An Evaluation of the Bioengineered COMBO Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Coronary Stent Compared With a Cobalt-Chromium Everolimus-Eluting Stent in Patients With Acute Coronary Syndromes: Insights From Optical Coherence Tomography Imaging Analysis. , 2017, JACC. Cardiovascular interventions.

[6]  G. Stone,et al.  First-in-Human Evaluation of a Novel Polymer-Free Drug-Filled Stent: Angiographic, IVUS, OCT, and Clinical Outcomes From the RevElution Study. , 2017, JACC. Cardiovascular interventions.

[7]  P. Fitzgerald,et al.  Comparative analysis method of permanent metallic stents (XIENCE) and bioresorbable poly-L-lactic (PLLA) scaffolds (Absorb) on optical coherence tomography at baseline and follow-up. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[8]  D. Izumi,et al.  Optical coherence tomography analysis of the stent strut and prediction of resolved strut malapposition at 3 months after 2nd-generation drug-eluting stent implantation , 2016, Heart and Vessels.

[9]  J. Airaksinen,et al.  Early vascular healing after titanium–nitride–oxide-coated stent versus platinum–chromium everolimus-eluting stent implantation in patients with acute coronary syndrome , 2016, The International Journal of Cardiovascular Imaging.

[10]  M. Yamaoka-Tojo,et al.  Neointimal coverage of zotarolimus-eluting stent at 1, 2, and 3 months’ follow-up: an optical coherence tomography study , 2016, Heart and Vessels.

[11]  F. Eberli,et al.  Polymer-free Drug-Coated Coronary Stents. , 2016, The New England journal of medicine.

[12]  Francesco Versaci,et al.  Clinical Impact of OCT Findings During PCI: The CLI-OPCI II Study. , 2015, JACC. Cardiovascular imaging.

[13]  Giuseppe Biondi-Zoccai,et al.  Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials , 2015, The Lancet.

[14]  M. Valgimigli,et al.  Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. , 2015, Journal of the American College of Cardiology.

[15]  E. Romagnoli,et al.  Randomized comparison between 3-month Cre8 DES vs. 1-month Vision/Multilink8 BMS neointimal coverage assessed by OCT evaluation: the DEMONSTRATE study. , 2014, International journal of cardiology.

[16]  Y. Jang,et al.  Long-term outcomes of neointimal hyperplasia without neoatherosclerosis after drug-eluting stent implantation. , 2014, JACC. Cardiovascular imaging.

[17]  P. Serruys,et al.  Impact of biodegradable versus durable polymer drug‐eluting stents on clinical outcomes in patients with coronary artery disease: a meta‐analysis of 15 randomized trials , 2014, Chinese Medical Journal.

[18]  J. Granada,et al.  Neointimal patterns obtained by optical coherence tomography correlate with specific histological components and neointimal proliferation in a swine model of restenosis. , 2014, European heart journal cardiovascular Imaging.

[19]  R. Whitbourn,et al.  Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography. , 2011, JACC. Cardiovascular interventions.

[20]  Patrick W Serruys,et al.  Serial analysis of the malapposed and uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold with optical coherence tomography. , 2011, JACC. Cardiovascular interventions.

[21]  Saibal Kar,et al.  Polymer-Free Biolimus A9–Coated Stent Demonstrates More Sustained Intimal Inhibition, Improved Healing, and Reduced Inflammation Compared With a Polymer-Coated Sirolimus-Eluting Cypher Stent in a Porcine Model , 2010, Circulation. Cardiovascular interventions.

[22]  J. Wilcox,et al.  Impact of polymer hydrophilicity on biocompatibility: implication for DES polymer design. , 2009, Journal of biomedical materials research. Part A.

[23]  J. Wilcox,et al.  Development of a novel biocompatible polymer system for extended drug release in a next-generation drug-eluting stent. , 2008, Journal of biomedical materials research. Part A.

[24]  Simon Wandel,et al.  Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.

[25]  Michael Joner,et al.  Vascular Responses to Drug Eluting Stents: Importance of Delayed Healing , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[26]  J. Wilcox,et al.  The next generation Endeavor Resolute Stent: role of the BioLinx Polymer System. , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[27]  H. Hecht,et al.  Lesion morphology and coronary angioplasty: current experience and analysis. , 1992, Journal of the American College of Cardiology.

[28]  K. Hirata,et al.  Qualitative and quantitative assessment of stent restenosis by optical coherence tomography: comparison between drug-eluting and bare-metal stents. , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[29]  Helmut Baumgartner,et al.  ESC / EACTS Guidelines on myocardial revascularization , 2014 .